Bank of America Upgrades Dentsply to Buy, Raises Price Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7 hours ago
0mins
Should l Buy XRAY?
Source: seekingalpha
- Rating Upgrade: Bank of America upgraded Dentsply Sirona (XRAY) from Neutral to Buy and raised its price target from $13 to $17, indicating a compelling risk-reward opportunity for the dental product manufacturer.
- Earnings Anticipation: Dentsply is set to release its Q4 2025 earnings next week, with analysts noting potential volatility in share price due to risks of a dividend cut by management.
- Market Outlook: Despite a more than 30% decline in stock price over the past 12 months, analysts believe the risk/reward for XRAY is finally skewing positive, with next week's 2026 outlook expected to be a pivotal event.
- Competitive Positioning: XRAY trades at its widest historical discount to rival Envista Holdings (NVST), and analysts suggest that even modest execution could lead to multiple expansion, enhancing its competitive advantage.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XRAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XRAY
Wall Street analysts forecast XRAY stock price to rise
16 Analyst Rating
2 Buy
13 Hold
1 Sell
Hold
Current: 12.490
Low
12.00
Averages
13.04
High
17.00
Current: 12.490
Low
12.00
Averages
13.04
High
17.00
About XRAY
DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. It develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices. Its Connected Technology Solutions segment includes design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of its value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and dental professional-directed aligner solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for urinary and bowel management.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Decline Amid AI Outlook Concerns
- Market Decline: The S&P 500 Index fell by 0.44%, the Dow Jones by 0.57%, and the Nasdaq 100 by 0.66%, reflecting market concerns over the outlook for artificial intelligence, particularly impacting chipmakers and AI infrastructure stocks.
- Mixed Economic Data: Weekly initial jobless claims dropped to 206,000, a five-week low, indicating a strong labor market; however, the December trade deficit widened to $70.3 billion, exceeding expectations, suggesting economic pressures that could affect market confidence.
- Earnings Season Nearing End: Over 75% of S&P 500 companies have reported earnings, with 75% exceeding expectations, and Q4 earnings growth projected at 8.4%, providing some support for the market, although overall sentiment remains cautious.
- Geopolitical Risks Intensify: WTI crude oil prices rose over 1% to a three-week high due to U.S. military buildup in the Middle East, heightening inflation concerns and potentially increasing expectations for Fed rate hikes.
See More
Bank of America Upgrades Dentsply to Buy, Raises Price Target
- Rating Upgrade: Bank of America upgraded Dentsply Sirona (XRAY) from Neutral to Buy and raised its price target from $13 to $17, indicating a compelling risk-reward opportunity for the dental product manufacturer.
- Earnings Anticipation: Dentsply is set to release its Q4 2025 earnings next week, with analysts noting potential volatility in share price due to risks of a dividend cut by management.
- Market Outlook: Despite a more than 30% decline in stock price over the past 12 months, analysts believe the risk/reward for XRAY is finally skewing positive, with next week's 2026 outlook expected to be a pivotal event.
- Competitive Positioning: XRAY trades at its widest historical discount to rival Envista Holdings (NVST), and analysts suggest that even modest execution could lead to multiple expansion, enhancing its competitive advantage.
See More
DENTSPLY SIRONA INC: BOFA GLOBAL RESEARCH UPGRADES TO BUY FROM NEUTRAL AND INCREASES PRICE TARGET TO $17 FROM $13
- Company Announcement: Dentply Sirona has announced a global research initiative to buy from Neutral.
- Price Increase: The objective price for the initiative has been raised from $13 to $17.
See More
Latest Rating Changes on Wall Street
- Nvidia Outlook Positive: Oppenheimer reiterates its outperform rating on Nvidia, anticipating sustained outsized growth in high-performance gaming, datacenter/AI, and autonomous driving, indicating strong market demand and future profitability potential.
- CIBC Rating Upgrade: Barclays upgrades CIBC from underweight to overweight, highlighting the bank's progress over the past two years with ROE expansion and consistent earnings performance, suggesting significant growth potential and investment appeal in the Canadian market.
- Credo Technology Buy Rating: Goldman Sachs initiates coverage of Credo Technology with a buy rating and a 12-month price target of $165, indicating a favorable risk/reward profile and confidence in the company's future growth.
- Chewy Rating Upgrade: Raymond James upgrades Chewy from market perform to outperform, noting an attractive EV/EBITDA of approximately 8x, combined with topline and margin opportunities in 2026, highlighting the stock's appeal.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, although specific upgrades and downgrades are not disclosed, this shift could influence investor decisions and market sentiment.
- Market Reaction Expectations: Changes in analyst ratings typically trigger market volatility, prompting investors to monitor these shifts to assess potential investment opportunities and risks, especially in the current economic climate.
- Investor Focus: For those considering buying CHWY stock, analysts' opinions will serve as a crucial reference point, potentially impacting their buying decisions and the stock's market performance.
- Rating Change Transparency: While the article does not provide specific details on rating changes, it emphasizes the importance of the analyst ratings page, where investors can access comprehensive information on rating changes to make informed investment choices.
See More
Analysis of XRAY's 52-Week High and Low Points
- Price Range Analysis: XRAY's stock has a 52-week low of $9.85 and a high of $19.27, with the last trade at $13.76, indicating stability within its trading range, which may attract investor interest.
- Technical Indicator Insight: The current stock price is above the 200-day moving average, suggesting a potential upward trend in the short term, which investors might consider as a buy signal.
- Market Sentiment Evaluation: Although the current price is below the 52-week high, it remains above the low, reflecting that market confidence in XRAY has not completely waned, potentially laying the groundwork for future rebounds.
- Investor Focus: XRAY's performance contrasts with nine other dividend stocks that recently crossed above their 200-day moving average, which may prompt investors to reassess its dividend yield potential.
See More
US Stocks Decline Amid AI Outlook Concerns
- Market Decline: The S&P 500 Index fell by 0.44%, the Dow Jones by 0.57%, and the Nasdaq 100 by 0.66%, reflecting market concerns over the outlook for artificial intelligence, particularly impacting chipmakers and AI infrastructure stocks.
- Mixed Economic Data: Weekly initial jobless claims dropped to 206,000, a five-week low, indicating a strong labor market; however, the December trade deficit widened to $70.3 billion, exceeding expectations, suggesting economic pressures that could affect market confidence.
- Earnings Season Nearing End: Over 75% of S&P 500 companies have reported earnings, with 75% exceeding expectations, and Q4 earnings growth projected at 8.4%, providing some support for the market, although overall sentiment remains cautious.
- Geopolitical Risks Intensify: WTI crude oil prices rose over 1% to a three-week high due to U.S. military buildup in the Middle East, heightening inflation concerns and potentially increasing expectations for Fed rate hikes.
See More
Bank of America Upgrades Dentsply to Buy, Raises Price Target
- Rating Upgrade: Bank of America upgraded Dentsply Sirona (XRAY) from Neutral to Buy and raised its price target from $13 to $17, indicating a compelling risk-reward opportunity for the dental product manufacturer.
- Earnings Anticipation: Dentsply is set to release its Q4 2025 earnings next week, with analysts noting potential volatility in share price due to risks of a dividend cut by management.
- Market Outlook: Despite a more than 30% decline in stock price over the past 12 months, analysts believe the risk/reward for XRAY is finally skewing positive, with next week's 2026 outlook expected to be a pivotal event.
- Competitive Positioning: XRAY trades at its widest historical discount to rival Envista Holdings (NVST), and analysts suggest that even modest execution could lead to multiple expansion, enhancing its competitive advantage.
See More
DENTSPLY SIRONA INC: BOFA GLOBAL RESEARCH UPGRADES TO BUY FROM NEUTRAL AND INCREASES PRICE TARGET TO $17 FROM $13
- Company Announcement: Dentply Sirona has announced a global research initiative to buy from Neutral.
- Price Increase: The objective price for the initiative has been raised from $13 to $17.
See More
Latest Rating Changes on Wall Street
- Nvidia Outlook Positive: Oppenheimer reiterates its outperform rating on Nvidia, anticipating sustained outsized growth in high-performance gaming, datacenter/AI, and autonomous driving, indicating strong market demand and future profitability potential.
- CIBC Rating Upgrade: Barclays upgrades CIBC from underweight to overweight, highlighting the bank's progress over the past two years with ROE expansion and consistent earnings performance, suggesting significant growth potential and investment appeal in the Canadian market.
- Credo Technology Buy Rating: Goldman Sachs initiates coverage of Credo Technology with a buy rating and a 12-month price target of $165, indicating a favorable risk/reward profile and confidence in the company's future growth.
- Chewy Rating Upgrade: Raymond James upgrades Chewy from market perform to outperform, noting an attractive EV/EBITDA of approximately 8x, combined with topline and margin opportunities in 2026, highlighting the stock's appeal.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, although specific upgrades and downgrades are not disclosed, this shift could influence investor decisions and market sentiment.
- Market Reaction Expectations: Changes in analyst ratings typically trigger market volatility, prompting investors to monitor these shifts to assess potential investment opportunities and risks, especially in the current economic climate.
- Investor Focus: For those considering buying CHWY stock, analysts' opinions will serve as a crucial reference point, potentially impacting their buying decisions and the stock's market performance.
- Rating Change Transparency: While the article does not provide specific details on rating changes, it emphasizes the importance of the analyst ratings page, where investors can access comprehensive information on rating changes to make informed investment choices.
See More
Analysis of XRAY's 52-Week High and Low Points
- Price Range Analysis: XRAY's stock has a 52-week low of $9.85 and a high of $19.27, with the last trade at $13.76, indicating stability within its trading range, which may attract investor interest.
- Technical Indicator Insight: The current stock price is above the 200-day moving average, suggesting a potential upward trend in the short term, which investors might consider as a buy signal.
- Market Sentiment Evaluation: Although the current price is below the 52-week high, it remains above the low, reflecting that market confidence in XRAY has not completely waned, potentially laying the groundwork for future rebounds.
- Investor Focus: XRAY's performance contrasts with nine other dividend stocks that recently crossed above their 200-day moving average, which may prompt investors to reassess its dividend yield potential.
See More
